US 12,171,865 B2
Bioactive polymer for bone regeneration
Ali Fathi, Northmead (AU); Fariba Dehghani, Killarney Heights (AU); Anthony Weiss, Randwick (AU); and Suzanne Mithieux, Randwick (AU)
Assigned to Trimph IP Pty Ltd, Sydney (AU)
Filed by Trimph IP Pty Ltd, Sydney (AU)
Filed on Nov. 5, 2020, as Appl. No. 17/090,078.
Application 17/090,078 is a continuation of application No. 15/753,556, abandoned, previously published as PCT/AU2016/050817, filed on Aug. 31, 2016.
Claims priority of application No. 2015903552 (AU), filed on Sep. 1, 2015.
Prior Publication US 2021/0093749 A1, Apr. 1, 2021
Int. Cl. A61K 9/00 (2006.01); A61F 2/28 (2006.01); A61K 31/787 (2006.01); A61K 38/17 (2006.01); A61K 38/39 (2006.01); A61K 47/32 (2006.01); A61K 47/42 (2017.01); A61L 27/16 (2006.01); A61L 27/22 (2006.01); A61L 27/24 (2006.01); A61L 27/52 (2006.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01); C08F 220/28 (2006.01); C08L 33/14 (2006.01); C08L 33/26 (2006.01); C08L 89/00 (2006.01)
CPC A61K 9/0019 (2013.01) [A61F 2/28 (2013.01); A61K 31/787 (2013.01); A61K 38/1709 (2013.01); A61K 38/39 (2013.01); A61K 47/32 (2013.01); A61K 47/42 (2013.01); A61L 27/16 (2013.01); A61L 27/227 (2013.01); A61L 27/24 (2013.01); A61L 27/52 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); C08L 33/14 (2013.01); C08L 33/26 (2013.01); C08L 89/00 (2013.01); A61F 2002/2817 (2013.01); A61L 2300/252 (2013.01); A61L 2300/412 (2013.01); A61L 2400/06 (2013.01); A61L 2430/02 (2013.01); C08F 220/282 (2020.02); C08F 220/285 (2020.02); C08L 2201/06 (2013.01); C08L 2201/54 (2013.01); C08L 2203/02 (2013.01)] 12 Claims
 
1. A method of treatment of a defect in a bone of a mammal, the method comprising introducing or administering a therapeutically effective amount of a polymer to said defect thereby to repair or restore said bone, the polymer comprising:
a first monomer for binding water, wherein the first monomer is oligo (ethylene) glycol monomethyl ether methacrylate (OEGMA);
a second monomer for imparting mechanical properties to said polymer, wherein the second monomer is hydroxyethyl methacrylate poly(lactic acid) (HEMA-PLA);
a third monomer for binding to a natural or synthetic peptide or protein (NSPP), wherein the third monomer is N-acryloxysuccinimide (NAS); and
a fourth monomer for imparting phase transition behaviour, wherein the fourth monomer is N-isopropylacrylamide (NIPAAm).